Combining Molecularly Targeted Agents: Is More Always Better?

Area of Science:

• Oncology
• Molecular Biology
• Clinical Pharmacology

Background:

• Targeted cancer therapies aim at specific molecular pathways.
• Concurrent targeting of multiple pathways is a rational antitumor strategy.
• Combination therapies have shown variable success and present unique challenges.

Purpose of the Study:

• To discuss the strategic rationale for concurrent targeting of signaling pathways.
• To highlight the challenges in developing combination molecularly targeted agents.
• To emphasize the importance of assessing combination efficacy and toxicity for clinical trial progression.

Main Methods:

• Review of current strategies in molecularly targeted therapy combinations.
• Discussion of toxicological and efficacy assessment methodologies.
• Analysis of decision-making processes for advancing combination therapies.

Main Results:

• Concurrent targeting is a rational approach but success is variable.
• Key challenges include managing synergistic toxicities.
• Establishing true combination activity is essential for "go, no-go" decisions.

Conclusions:

• Combination molecularly targeted agents require careful evaluation.
• Overcoming toxicity and demonstrating efficacy are critical hurdles.
• Rigorous assessment is necessary before advancing to later-phase clinical trials.